MX343801B - Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama. - Google Patents
Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama.Info
- Publication number
- MX343801B MX343801B MX2013000673A MX2013000673A MX343801B MX 343801 B MX343801 B MX 343801B MX 2013000673 A MX2013000673 A MX 2013000673A MX 2013000673 A MX2013000673 A MX 2013000673A MX 343801 B MX343801 B MX 343801B
- Authority
- MX
- Mexico
- Prior art keywords
- breast cancer
- expression
- level
- blood plasma
- metastatic
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a métodos para mejorar el efecto de tratamiento de un régimen de quimioterapia de un paciente que sufre cáncer de mama, en particular cáncer de mama negativo HER-2 localmente avanzado, recurrente o metastásico, al agregar bevacizumab (Avastin(r)) a un régimen de quimioterapia, al determinar el nivel de expresión, en particular el nivel de expresión en plasma de sangre, de uno o más de VEGFA, VEGFR2 y PLGF respecto a niveles de control de pacientes diagnosticados con cáncer de mama, en particular cáncer de mama negativo HER-2 localmente avanzado, recurrente o metastásico. En particular, la presente invención proporciona métodos para mejorar el efecto de tratamiento, en donde el efecto de tratamiento es la supervivencia libre de progreso del paciente. La presente invención además proporciona métodos para estimar la sensibilidad o respuesta de un paciente a bevacizumab (Avastin(r)) en combinación con un régimen de quimioterapia, al determinar el nivel de expresión, en particular el nivel de expresión en plasma de sangre, de uno o más de VEGFA, VEGFR2 y PLGF respecto a niveles de control en pacientes con diagnóstico de cáncer de mama, en particular cáncer de mama negativo HER-2 localmente avanzado, recurrente o metastásico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10170008 | 2010-07-19 | ||
| PCT/EP2011/062232 WO2012010552A1 (en) | 2010-07-19 | 2011-07-18 | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013000673A MX2013000673A (es) | 2013-02-27 |
| MX343801B true MX343801B (es) | 2016-11-23 |
Family
ID=44545675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013000673A MX343801B (es) | 2010-07-19 | 2011-07-18 | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20130121999A1 (es) |
| EP (2) | EP2596363B1 (es) |
| JP (1) | JP6055764B2 (es) |
| KR (1) | KR20130091750A (es) |
| CN (2) | CN103109188B (es) |
| AU (1) | AU2011281706A1 (es) |
| BR (1) | BR112013001423A2 (es) |
| CA (1) | CA2804350A1 (es) |
| ES (1) | ES2619590T3 (es) |
| HK (1) | HK1217093A1 (es) |
| MX (1) | MX343801B (es) |
| NZ (1) | NZ603780A (es) |
| RU (1) | RU2013106938A (es) |
| SG (1) | SG187013A1 (es) |
| WO (1) | WO2012010552A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TH121482A (th) | 2009-08-19 | 2013-02-28 | นางสาวปัณณพัฒน์ เหลืองธาตุทอง | องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน |
| MX2012008153A (es) * | 2010-01-12 | 2012-11-06 | Nestec Sa | Metodos para predecir la respuesta a terapia de cancer de mama triple negativo. |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| WO2013083499A1 (en) * | 2011-12-05 | 2013-06-13 | F. Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
| US9116159B2 (en) | 2012-05-22 | 2015-08-25 | Regeneron Pharmaceuticals, Inc. | VEGF-A121 assay |
| KR20230043234A (ko) | 2014-08-28 | 2023-03-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| MX2017006201A (es) * | 2014-11-14 | 2017-07-31 | Genentech Inc | Respuesta de prediccion a un antagonista de vegf. |
| US11220545B2 (en) | 2014-12-08 | 2022-01-11 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| CA2994925C (en) | 2015-08-20 | 2023-08-29 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| EP3362074B1 (en) | 2015-10-16 | 2023-08-09 | President and Fellows of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
| WO2017165412A2 (en) | 2016-03-21 | 2017-09-28 | Dana-Farber Cancer Institute, Inc. | T-cell exhaustion state-specific gene expression regulators and uses thereof |
| US9950070B2 (en) | 2016-08-16 | 2018-04-24 | Korea University Research And Business Foundation | HER2 aptamer-anticancer drug complex for cancer cell chemotherapy |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
| KR102247908B1 (ko) | 2020-10-08 | 2021-05-06 | 주식회사 엠디엡투스 | Her2 압타머-항암 약물 복합체 및 이의 용도 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19806989A1 (de) | 1998-02-19 | 1999-08-26 | Roche Diagnostics Gmbh | Erzeugung räumlich scharf begrenzter Festphasen für Bindungsassays |
| US7435419B2 (en) * | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| DK2308507T3 (da) * | 2002-07-19 | 2015-04-20 | Beth Israel Hospital | Fremgangsmåder til behandling af præeklampsi |
| DE102004029909A1 (de) | 2004-06-21 | 2006-01-19 | Roche Diagnostics Gmbh | Verfahren und Vorrichtung zur Herstellung von bindungsfähigen Reagenzträgern |
| CN101068561A (zh) * | 2004-10-06 | 2007-11-07 | 蒂尔坦制药有限公司 | 用于加强抗血管生成疗法的方法和组合物 |
| KR20080073745A (ko) * | 2005-11-14 | 2008-08-11 | 바이엘 헬스케어 엘엘씨 | 암의 예측 및 예후 방법, 및 암 치료 요법을 모니터하는방법 |
| CA2672618C (en) * | 2006-12-14 | 2021-03-02 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| EP2109686A2 (en) * | 2007-01-18 | 2009-10-21 | University Of Southern California | Genetic markers for predicting responsiveness to combination therapy |
| JP2010518013A (ja) * | 2007-02-01 | 2010-05-27 | ジェネンテック， インコーポレイテッド | 血管形成阻害剤を含む組み合わせ治療の方法 |
| EP2065399A1 (en) * | 2007-11-30 | 2009-06-03 | Siemens Healthcare Diagnostics GmbH | The present invention relates to methods for prediction of the therapeutic success of breast cancer therapy |
| AU2008334070B2 (en) * | 2007-11-30 | 2015-04-16 | Genentech, Inc. | VEGF polymorphisms and anti-angiogenesis therapy |
| US20100004306A1 (en) * | 2008-06-18 | 2010-01-07 | Abbott Laboratories | PIGF-1 Assay and kits and components thereof |
| JP5416221B2 (ja) * | 2008-12-23 | 2014-02-12 | ジェネンテック， インコーポレイテッド | 癌患者における診断用途のための方法および組成物 |
-
2011
- 2011-07-18 KR KR1020137004172A patent/KR20130091750A/ko not_active Ceased
- 2011-07-18 WO PCT/EP2011/062232 patent/WO2012010552A1/en not_active Ceased
- 2011-07-18 ES ES11746191.3T patent/ES2619590T3/es active Active
- 2011-07-18 NZ NZ60378011A patent/NZ603780A/en not_active IP Right Cessation
- 2011-07-18 BR BR112013001423A patent/BR112013001423A2/pt not_active IP Right Cessation
- 2011-07-18 CN CN201180044840.2A patent/CN103109188B/zh not_active Expired - Fee Related
- 2011-07-18 JP JP2013520106A patent/JP6055764B2/ja not_active Expired - Fee Related
- 2011-07-18 EP EP11746191.3A patent/EP2596363B1/en not_active Not-in-force
- 2011-07-18 RU RU2013106938/15A patent/RU2013106938A/ru not_active Application Discontinuation
- 2011-07-18 AU AU2011281706A patent/AU2011281706A1/en not_active Abandoned
- 2011-07-18 CN CN201510684543.4A patent/CN105327347A/zh active Pending
- 2011-07-18 SG SG2013001946A patent/SG187013A1/en unknown
- 2011-07-18 MX MX2013000673A patent/MX343801B/es active IP Right Grant
- 2011-07-18 CA CA2804350A patent/CA2804350A1/en not_active Abandoned
- 2011-07-18 EP EP16184951.8A patent/EP3156800A1/en not_active Withdrawn
-
2012
- 2012-12-27 US US13/728,411 patent/US20130121999A1/en not_active Abandoned
-
2013
- 2013-03-13 US US13/801,914 patent/US20130183302A1/en not_active Abandoned
- 2013-03-13 US US13/801,923 patent/US20130183303A1/en not_active Abandoned
- 2013-10-30 HK HK16105145.5A patent/HK1217093A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20130183302A1 (en) | 2013-07-18 |
| CA2804350A1 (en) | 2012-01-26 |
| CN103109188B (zh) | 2015-11-25 |
| HK1184854A1 (zh) | 2014-01-30 |
| NZ603780A (en) | 2015-04-24 |
| WO2012010552A1 (en) | 2012-01-26 |
| KR20130091750A (ko) | 2013-08-19 |
| JP2013534308A (ja) | 2013-09-02 |
| HK1217093A1 (zh) | 2016-12-23 |
| ES2619590T3 (es) | 2017-06-26 |
| CN103109188A (zh) | 2013-05-15 |
| MX2013000673A (es) | 2013-02-27 |
| US20130121999A1 (en) | 2013-05-16 |
| US20130183303A1 (en) | 2013-07-18 |
| EP2596363B1 (en) | 2017-01-18 |
| EP3156800A1 (en) | 2017-04-19 |
| JP6055764B2 (ja) | 2016-12-27 |
| EP2596363A1 (en) | 2013-05-29 |
| RU2013106938A (ru) | 2014-08-27 |
| AU2011281706A1 (en) | 2013-01-10 |
| CN105327347A (zh) | 2016-02-17 |
| BR112013001423A2 (pt) | 2016-05-24 |
| SG187013A1 (en) | 2013-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX343801B (es) | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama. | |
| MX339427B (es) | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico. | |
| AR089067A1 (es) | Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama | |
| MY172580A (en) | Tumor tissue based biomarkers for bevacizumab combination therapies | |
| MX358541B (es) | Metodos para predecir el riesgo de desarrollar hipertension. | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| MX2018012580A (es) | Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia. | |
| MX2019000091A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| MY188938A (en) | Therapeutic, diagnostic and prognostic methods for cancer of the bladder | |
| TN2013000358A1 (en) | Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects | |
| MX2013002084A (es) | Biomarcadores y metodos de tratamiento. | |
| BR112014025189A2 (pt) | prognóstico de eventos adversos em pacientes com suspeita de insuficiência cardíaca crônica | |
| BR112013006683A2 (pt) | diagnóstico de câncer de mama | |
| HK1208057A1 (en) | Breast cancer prognosis, prediction of progesterone receptor subtype and prediction of response to antiprogestin treatment based on gene expression | |
| BR112014024219A8 (pt) | Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit | |
| WO2011094759A3 (en) | Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies | |
| MX360236B (es) | Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. | |
| MX2016012285A (es) | Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf. | |
| WO2014078468A3 (en) | Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent | |
| WO2012044696A3 (en) | Prediction of clinical outcome in hematological malignancies using a self-renewal expression signature | |
| EA201700123A1 (ru) | Способ прогнозирования варианта лекарственного препарата для лечения депрессии | |
| BR112015004653A2 (pt) | método diagnóstico e terapêutico de câncer de moléculas alvo expressas em células-tronco cancerígenas | |
| MX2016002529A (es) | Marcadores de riesgo para cardiovasculopatias en pacientes con nefropatia cronica. | |
| MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
| WO2015036643A3 (es) | Marcador para predecir metástasis del cáncer de mama |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |